|Assessment Status||Rapid Review Complete|
|Indication||For the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.|
|Rapid review commissioned||30/08/2021|
|Rapid review completed||08/10/2021|
|Rapid review outcome||A full HTA is not recommended. The NCPE recommends that ponesimod (Ponvory®) not be considered for reimbursement at the submitted price. *|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.
The HSE has approved reimbursement following confidential price negotiations January 2022.